| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8545879 | TERSERA | Fast disintegrating compositions of meloxicam |
Aug, 2030
(6 years from now) | |
Qmiiz Odt is owned by Tersera.
Qmiiz Odt contains Meloxicam.
Qmiiz Odt has a total of 1 drug patent out of which 0 drug patents have expired.
Qmiiz Odt was authorised for market use on 19 October, 2018.
Qmiiz Odt is available in tablet, orally disintegrating;oral dosage forms.
The generics of Qmiiz Odt are possible to be released after 31 August, 2030.
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 19 October, 2018
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
QMIIZ ODT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic